Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
mice, accumulation of GMP and MDSC was prevented, whereas systemic output of effector myeloid cells was increased. Myeloid cell-specific PD-1 ablation induced an increase of T effector memory cells with improved functionality and mediated antitumor protection despite preserved PD-1 expression in T cells. In PD-1-deficient myeloid progenitors, growth factors driving emergency myelopoiesis induced increased metabolic intermediates of glycolysis, pentose phosphate pathway, and TCA cycle but, most prominently, elevated cholesterol. Because cholesterol is required for differentiation of inflammatory macrophages and DC and promotes antigen-presenting function, our findings indicate that metabolic reprogramming of emergency myelopoiesis and differentiation of effector myeloid cells might be a key mechanism of antitumor immunity mediated by PD-1 blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PD-1 can be expressed on some myeloid cells as well, and changes in the myeloid compartment could lead to an influx of inflammatory cells into various, distant tissues/organs and inciting organ damage”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Strauss et al., 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247 · cited 2×
“However, similar to its role in infections, PD-1 expression inversely correlates with M1 polarization and phagocytic potency of tumor-associated M (TAM) against tumor (7, 8).”
BackgroundActivation of a metabolic gene regulatory network downstream of mTOR complex 1
Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797 · cited 2×
“Myeloid-specific PD-1 ablation induces improved T cell functionality Previously, it was determined that monocyte/macrophage terminal differentiation is controlled by the combined actions of retinoid receptors and the nuclear receptor peroxisome proliferator–activated receptor (PPAR), which is regulated by cholester…”
BackgroundSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Cited by
Macrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Hiam-Galvez, K. J., Allen, B. M., & Spitzer, M. H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00347-z · Cited by 1,400
Neutrophil diversity and plasticity in tumour progression and therapy
Jaillon, S., Ponzetta, A., Di Mitri, D., Santoni, A., Bonecchi, R., & Mantovani, A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0281-y · Cited by 1,285
Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy
Bader, J. E., Voss, K., & Rathmell, J. C. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.034 · Cited by 1,030
“For example, myeloid cell-specific ablation of PD-1 more effectively decreased tumor growth than T cell-specific ablation, yet the metabolic impact of PD-1 blockade on myeloid cells remains uncertain (Strauss et al., 2020).”
BackgroundTargeting tumor-associated macrophages to synergize tumor immunotherapy
Xiang, X., Wang, J., Lu, D., & Xu, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00484-9 · Cited by 966
“Another recent study based on a myeloid cell-specific PD-1 silencing model revealed the vital role of elevated intracellular cholesterol during anti-PD-1 treatment, which is required for differentiation of inflammatory macrophages and the promotion of antigen-presenting function.(91) These findings show the complexity…”
BackgroundThe complex role of tumor-infiltrating macrophages
Christofides, A., Strauss, L., Yeo, A., Cao, C., Charest, A., & Boussiotis, V. A. (2022) · Nature Immunology · doi:10.1038/s41590-022-01267-2 · Cited by 849
Self-citationThe CD47-SIRPα Immune Checkpoint
Logtenberg, M. E. W., Scheeren, F. A., & Schumacher, T. N. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.011 · Cited by 735
“As a side note, PD-1 is expressed in myeloid cells in tumor-bearing mice, and the observed synergy between PD-L1 and CD47 blockade may in theory also be explained by a role of PD-1 as an inhibitory receptor in myeloid cells, as shown in recent mouse experiments (Strauss et al., 2020).”
BackgroundThe role of peroxisome proliferator-activated receptors (PPAR) in immune responses
Christofides, A., Konstantinidou, E., Jani, C., & Boussiotis, V. A. (2021) · Metabolism · doi:10.1016/j.metabol.2020.154338 · Cited by 720
Self-citationMetabolic programming and immune suppression in the tumor microenvironment
Arner, E. N., & Rathmell, J. C. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.009 · Cited by 668
Drobni, Z. D., Alvi, R. M., Taron, J., Zafar, A., Murphy, S. P., Rambarat, P. K., Mosarla, R. C., Lee, C., Zlotoff, D. A., Raghu, V. K., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.049981 · Cited by 560
Peng, Q., Qiu, X., Zhang, Z., Zhang, S., Zhang, Y., Liang, Y., Guo, J., Peng, H., Chen, M., Fu, Y.-X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18570-x · Cited by 553
Navigating CAR-T cells through the solid-tumour microenvironment
Hou, A. J., Chen, L. C., & Chen, Y. Y. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00189-2 · Cited by 551
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
Korman, A. J., Garrett-Thomson, S. C., & Lonberg, N. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00345-8 · Cited by 548
Patsoukis, N., Wang, Q., Strauss, L., & Boussiotis, V. A. (2020) · Science Advances · doi:10.1126/sciadv.abd2712 · Cited by 535
Self-citationMyeloid-derived suppressor cells in cancer and cancer therapy
Lasser, S. A., Ozbay Kurt, F. G., Arkhypov, I., Utikal, J., & Umansky, V. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00846-y · Cited by 489
“93) or CTLA4 (ref.”
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
Mayoux, M., Roller, A., Pulko, V., Sammicheli, S., Chen, S., Sum, E., Jost, C., Fransen, M. F., Buser, R. B., Kowanetz, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7431 · Cited by 394
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer
Voabil, P., de Bruijn, M., Roelofsen, L. M., Hendriks, S. H., Brokamp, S., van den Braber, M., Broeks, A., Sanders, J., Herzig, P., Zippelius, A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01398-3 · Cited by 380
Immunologic tumor microenvironment modulators for turning cold tumors hot
Khosravi, G., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · Cancer Communications · doi:10.1002/cac2.12539 · Cited by 364
“PD-1 can also be expressed on certain myeloid cells, and alterations within the myeloid compartment may lead to an influx of inflammatory cells into various distant tissues and organs, potentially inciting organ damage [204, 205].”
BackgroundKürten, C. H. L., Kulkarni, A., Cillo, A. R., Santos, P. M., Roble, A. K., Onkar, S., Reeder, C., Lang, S., Chen, X., Duvvuri, U., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27619-4 · Cited by 293
Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression
Yeo, A. T., Rawal, S., Delcuze, B., Christofides, A., Atayde, A., Strauss, L., Balaj, L., Rogers, V. A., Uhlmann, E. J., Varma, H., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01215-0 · Cited by 290
Self-citationHack, S. P., Zhu, A. X., & Wang, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.598877 · Cited by 286
“Specifically, selective PD-1 ablation in myeloid cells was found to be more effective at inhibiting tumor growth than global PD-1 deletion in T cells (85, 86).”
BackgroundHorvath, L., Thienpont, B., Zhao, L., Wolf, D., & Pircher, A. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01260-z · Cited by 283
“These data underline the important role of myeloid-intrinsic effects in regulating anti-tumor immunity [32].”
BackgroundCAR T cell therapy and the tumor microenvironment: Current challenges and opportunities
Kankeu Fonkoua, L. A., Sirpilla, O., Sakemura, R., Siegler, E. L., & Kenderian, S. S. (2022) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2022.03.009 · Cited by 282
Sattiraju, A., Kang, S., Giotti, B., Chen, Z., Marallano, V. J., Brusco, C., Ramakrishnan, A., Shen, L., Tsankov, A. M., Hambardzumyan, D., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.017 · Cited by 279
Contradictory roles of lipid metabolism in immune response within the tumor microenvironment
Yu, W., Lei, Q., Yang, L., Qin, G., Liu, S., Wang, D., Ping, Y., & Zhang, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01200-4 · Cited by 266
“This results in effective innate and adaptive antitumor responses [111].”
BackgroundLee, A. H., Sun, L., Mochizuki, A. Y., Reynoso, J. G., Orpilla, J., Chow, F., Kienzler, J. C., Everson, R. G., Nathanson, D. A., Bensinger, S. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26940-2 · Cited by 251
Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment
Arrieta, V. A., Dmello, C., McGrail, D. J., Brat, D. J., Lee-Chang, C., Heimberger, A. B., Chand, D., Stupp, R., & Sonabend, A. M. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163447 · Cited by 240
“Myeloid-specific PD-1 targeting induced antitumoral effects (77).”
Tumor-associated myeloid cells: diversity and therapeutic targeting
Mantovani, A., Marchesi, F., Jaillon, S., Garlanda, C., & Allavena, P. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00613-4 · Cited by 219
The cholesterol pathway: impact on immunity and cancer
King, R. J., Singh, P. K., & Mehla, K. (2022) · Trends in Immunology · doi:10.1016/j.it.2021.11.007 · Cited by 207
Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis
Dolladille, C., Akroun, J., Morice, P.-M., Dompmartin, A., Ezine, E., Sassier, M., Da-Silva, A., Plane, A.-F., Legallois, D., L’Orphelin, J.-M., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab618 · Cited by 205
Obradovic, A., Graves, D., Korrer, M., Wang, Y., Roy, S., Naveed, A., Xu, Y., Luginbuhl, A., Curry, J., Gibson, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3570 · Cited by 200
Targeting of TAMs: can we be more clever than cancer cells?
Kzhyshkowska, J. G., Shen, J., & Larionova, I. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01232-z · Cited by 201
“Myeloid-speci fi c PD-1 targeting can play a decisive role in systemic antitumor responses [152].”
Age-associated remodeling of T cell immunity and metabolism
Han, S., Georgiev, P., Ringel, A. E., Sharpe, A. H., & Haigis, M. C. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.005 · Cited by 193
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
Chamoto, K., Yaguchi, T., Tajima, M., & Honjo, T. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00867-9 · Cited by 185
“PD1 has been shown to have a critical role in regulating the composition of microbiota in the gut 113 .”
BackgroundHsieh, R. C.-E., Krishnan, S., Wu, R.-C., Boda, A. R., Liu, A., Winkler, M., Hsu, W.-H., Lin, S. H., Hung, M.-C., Chan, L.-C., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abl9330 · Cited by 182
The tumor microenvironment’s role in the response to immune checkpoint blockade
Aliazis, K., Christofides, A., Shah, R., Yeo, Y. Y., Jiang, S., Charest, A., & Boussiotis, V. A. (2025) · Nature Cancer · doi:10.1038/s43018-025-00986-3 · Cited by 178
“Under these conditions, genetic ablation or blockade of PD-1 or SHP-2, resulted in enhanced GM-CSF-mediated signaling in HSPCs as well as enhanced differentiation, effector function and diminished suppressor capacity of BM-derived myeloid cells, which no longer display properties of MDSCs 34,50 .”
InfluentialSelf-citationDatta, J., Dai, X., Bianchi, A., De Castro Silva, I., Mehra, S., Garrido, V. T., Lamichhane, P., Singh, S. P., Zhou, Z., Dosch, A. R., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.07.076 · Cited by 178
TNF in the era of immune checkpoint inhibitors: friend or foe?
Chen, A. Y., Wolchok, J. D., & Bass, A. R. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00584-4 · Cited by 183
Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications
Himes, B. T., Geiger, P. A., Ayasoufi, K., Bhargav, A. G., Brown, D. A., & Parney, I. F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.770561 · Cited by 170
“A recent murine study by Strauss and colleagues demonstrated that selective deletion of PD-1 in myeloid cells, in contrast to T cells, lead to better tumor control in a melanoma model (110).”
BackgroundObesity induces PD-1 on macrophages to suppress anti-tumour immunity
Bader, J. E., Wolf, M. M., Lupica-Tondo, G. L., Madden, M. Z., Reinfeld, B. I., Arner, E. N., Hathaway, E. S., Steiner, K. K., Needle, G. A., Hatem, Z., et al. (2024) · Nature · doi:10.1038/s41586-024-07529-3 · Cited by 167
Self-citationImmunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 162
“241,242 249 The use of PD-1 blockade can also induce anti-PD-1 resistance by induction of dysfunctional PD-1 + CD38 high CD8 + cells.”
BackgroundSmalley, I., Chen, Z., Phadke, M., Li, J., Yu, X., Wyatt, C., Evernden, B., Messina, J. L., Sarnaik, A., Sondak, V. K., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1694 · Cited by 161
“Recent preclinical work has supported a role for PD-1 inhibition in shaping myeloid lineages away from immunosuppressive phenotypes into differentiation programs that favor systemic tumor immunity mediated through DCs and effector monocytes (43).”
BackgroundZheng, Y., Han, Y., Sun, Q., & Li, Z. (2022) · Exploration · doi:10.1002/exp.20210166 · Cited by 169
Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy
Peng, X., He, Y., Huang, J., Tao, Y., & Liu, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.613492 · Cited by 146
“As a result, the metabolic intermediates were increased, especially cholesterol, which promoted the differentiation and antigen presentation of DCs (144).”
BackgroundIL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction
Shiri, A. M., Zhang, T., Bedke, T., Zazara, D. E., Zhao, L., Lücke, J., Sabihi, M., Fazio, A., Zhang, S., Tauriello, D. V. F., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.12.015 · Cited by 158
Recent advances in therapeutic cancer vaccines
Zaidi, N., Jaffee, E. M., & Yarchoan, M. M. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00820-z · Cited by 163
“In addition, the role of other immune cells, including B cells and myeloid cells, in mediating ICI-induced immunity is gaining increased recognition 5,6 .”
Macrophage‐Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention
Zhou, X., Liu, X., & Huang, L. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202006220 · Cited by 147
The B7:CD28 family and friends: Unraveling coinhibitory interactions
Burke, K. P., Chaudhri, A., Freeman, G. J., & Sharpe, A. H. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.013 · Cited by 155
Zhang, L., Reynolds, K. L., Lyon, A. R., Palaskas, N., & Neilan, T. G. (2021) · JACC: CardioOncology · doi:10.1016/j.jaccao.2020.11.012 · Cited by 141
Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer
Wang, Y., Wang, Y., Ren, Y., Zhang, Q., Yi, P., & Cheng, C. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.010 · Cited by 153
Wang, G., Chow, R. D.-W., Zhu, L., Bai, Z., Ye, L., Zhang, F., Renauer, P. A., Dong, M. B., Dai, X., Zhang, X., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1448 · Cited by 148
“Recent work has demonstrated that PD-1 blockade promotes antitumor immunity not only through its action on T cells, but also by leveraging myeloid-derived innate immune cells toward antitumor function (31, 41).”
BackgroundHolistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Poto, R., Troiani, T., Criscuolo, G., Marone, G., Ciardiello, F., Tocchetti, C. G., & Varricchi, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804597 · Cited by 146
Klement, J. D., Redd, P. S., Lu, C., Merting, A. D., Poschel, D. B., Yang, D., Savage, N. M., Zhou, G., Munn, D. H., Fallon, P. G., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.005 · Cited by 141
Systemic Reprogramming of Monocytes in Cancer
Kiss, M., Caro, A. A., Raes, G., & Laoui, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01399 · Cited by 147
Rethinking immune checkpoint blockade: ‘Beyond the T cell’
Liu, X., Hogg, G. D., & DeNardo, D. G. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001460 · Cited by 130
The role of ROS in tumor infiltrating immune cells and cancer immunotherapy
Shah, R., Ibis, B., Kashyap, M., & Boussiotis, V. A. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155747 · Cited by 130
Self-citationPD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury
Triantafyllou, E., Gudd, C. L. C., Mawhin, M.-A., Husbyn, H. C., Trovato, F. M., Siggins, M. K., O’Connor, T., Kudo, H., Mukherjee, S. K., Wendon, J. A., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140196 · Cited by 114
“PD-1 expression in myeloid cells was very recently shown to dampen antitumor immunity by regulating myeloid cell lineage fate commitment and function (27).”
Dyck, L., Prendeville, H., Raverdeau, M., Wilk, M. M., Loftus, R. M., Douglas, A., McCormack, J., Moran, B., Wilkinson, M., Mills, E. L., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20210042 · Cited by 123
“, 2015) or myeloid cells (Strauss et al., 2020), could have played a role as well, suggesting that anti–PD-1 exerts its effect through multiple mechanisms.”
BackgroundMyeloid-Derived Suppressor Cells in Solid Tumors
Ma, T., Renz, B. W., Ilmer, M., Koch, D. T., Yang, Y., Werner, J., & Bazhin, A. V. (2022) · Cells · doi:10.3390/cells11020310 · Cited by 122
PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance
van Gulijk, M., van Krimpen, A., Schetters, S., Eterman, M., van Elsas, M., Mankor, J., Klaase, L., de Bruijn, M., van Nimwegen, M., van Tienhoven, T., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.abn6173 · Cited by 110
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma
Arrieta, V. A., Chen, A. X., Kane, J. R., Kang, S. J., Kassab, C., Dmello, C., Zhao, J., Burdett, K. B., Upadhyayula, P. S., Lee-Chang, C., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00260-2 · Cited by 107
Made to order: emergency myelopoiesis and demand-adapted innate immune cell production
Swann, J. W., Olson, O. C., & Passegue, E. A. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-00998-7 · Cited by 116
“…targeted deletion of the immune-checkpoint molecule programmed cell death 1 (PD1) in myeloid cells but not in T cells induces antitumour immunity 163 , while tumour-driven activation of EM pathways upregulates PD1 on GMPs, in which it drives metabolic adaptation and generation of MDSCs 163 .”
Atherosclerosis With Immune Checkpoint Inhibitor Therapy
Suero‐Abreu, G. A., Zanni, M. V., & Neilan, T. G. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.11.011 · Cited by 107
Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad
Bleve, A., Durante, B., Sica, A., & Consonni, F. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165845 · Cited by 111
Macrophages in Skin Wounds: Functions and Therapeutic Potential
Sim, S.-L., Kumari, S., Kaur, S., & Khosrotehrani, K. (2022) · Biomolecules · doi:10.3390/biom12111659 · Cited by 107
SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses
Christofides, A., Katopodi, X.-L., Cao, C., Karagkouni, D., Aliazis, K., Yenyuwadee, S., Aksoylar, H., Pal, R., Mahmoud, M. A. A., Strauss, L., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01385-x · Cited by 100
Self-citationKluger, H. M., Barrett, J. C., Gainor, J. F., Hamid, O., Hurwitz, M. E., LaVallee, T. M., Moss, R. A., Zappasodi, R., Sullivan, R. J., Tawbi, H. A., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005921 · Cited by 102
“16 17 LAG3 is also expressed on exhausted T cells in tumors and canonically binds to major histocompatibility complex class II.”
Thomas, M. F., Slowikowski, K., Manakongtreecheep, K., Sen, P., Samanta, N., Tantivit, J., Nasrallah, M., Zubiri, L., Smith, N. P., Tirard, A. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02895-x · Cited by 107
Lymphatic PD-L1 expression restricts tumor-specific CD8+ T-cell responses
Cousin, N., Cap, S., Dihr, M., Tacconi, C., Detmar, M., & Dieterich, L. C. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0633 · Cited by 95
“24 Strauss, L. et al. Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. Sci. Immunol. 5, doi:10.1126/sciimmunol.aay1863 (2020). 25 Sharpe, A.”
InfluentialQuintana, E., Schulze, C. J., Myers, D. R., Choy, T. J., Mordec, K., Wildes, D., Shifrin, N. T., Belwafa, A., Koltun, E. S., Gill, A. L., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3038 · Cited by 94
“PD-1 signaling in myeloid cells can dampen antitumor immunity by regulating lineage fate commitment and function of myeloid cells (59).”
BackgroundIbis, B., Aliazis, K., Cao, C., Yenyuwadee, S., & Boussiotis, V. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1197364 · Cited by 99
“Parallel studies revealed that PD-1 expression in myeloid cells has an important role in lineage fate commitment, effector differentiation and antigen presenting function (14).”
BackgroundSelf-citationXiao, L., Zhang, L., Guo, C., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2024) · 癌症:英文版 · doi:10.1002/cac2.12579 · Cited by 96
“PD-1 + TAMs exhibit a phenotype resembling that of M2-like macrophages and demonstrate reduced phagocytic capacity toward cancer cells [358, 359].”
BackgroundImmune escape and resistance to immunotherapy in mismatch repair deficient tumors
Mestrallet, G., Brown, M., Bozkus, C. C., & Bhardwaj, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1210164 · Cited by 97
“MSI-H tumors accumulate monocyte, granulocyte and neutrophil populations as noted earlier (47, 55) (Figures 3C, D).”
BackgroundGeneration of Myeloid Cells in Cancer: The Spleen Matters
Wu, C., Hua, Q., & Zheng, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01126 · Cited by 99
Kim, M. J., Kim, K., Park, H. J., Kim, G.-R., Hong, K. H., Oh, J. H., Son, J., Park, D. J., Kim, D., Choi, J.-M., et al. (2023) · Nature Immunology · doi:10.1038/s41590-022-01373-1 · Cited by 90
Chamseddine, A. N., Assi, T., Mir, O., & Chouaïb, S. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107986 · Cited by 94
The complexity of immune evasion mechanisms throughout the metastatic cascade
Haynes, N. M., Chadwick, T. B., & Parker, B. S. (2024) · Nature Immunology · doi:10.1038/s41590-024-01960-4 · Cited by 93
“Notably, these MDSCs also express PD-1, enabling the negative regulation of T cell function 62 .”
Biology and therapeutic targeting of tumour‐associated macrophages
Beltraminelli, T., & De Palma, M. (2020) · The Journal of Pathology · doi:10.1002/path.5403 · Cited by 86
Lim, H. X., Kim, T. S., & Poh, C. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103599 · Cited by 89
“Deleting PD-1 from myeloid cells when compared to deleting it from T cells in mice led to a more significant reduction in tumor growth [61].”
BackgroundPembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
Goswami, M., Gui, G., Dillon, L. W., Lindblad, K. E., Thompson, J., Valdez, J., Kim, D., Ghannam, J. Y., Oetjen, K. A., DeStefano, C. B., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003392 · Cited by 88
IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Moynihan, K. D., Kumar, M. P., Sultan, H., Pappas, D. C., Park, T., Chin, S. M., Bessette, P. H., Lan, R. Y., Nguyen, H. C., Mathewson, N. D., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1266 · Cited by 84
“However, PD-1 expression has been documented in a variety of immune cells, including Tregs (70), myeloid cells (71, 72), γδ T cells (73), NK cells (74), and innate lymphoid cells (75).”
Tumor-associated myeloid cells in cancer immunotherapy
Cheng, X., Wang, H., Wang, Z., Zhu, B., & Long, H. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01473-x · Cited by 93
“Interestingly, studies have shown that the blockade of PD-1-mediated signals, as a representative ICB therapy, can diminish the accumulation of immunosuppressive and tumor-promoting MDSCs, skewing the myeloid lineage fate to mature myeloid effector cells [111].”
BackgroundChen, M., Lu, H., Copley, S. J., Han, Y., Logan, A., Viola, P., Cortellini, A., Pinato, D. J., Power, D., & Aboagye, E. O. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.01.089 · Cited by 82
Review of immune checkpoint inhibitors in immuno-oncology
Jacob, J. B., Jacob, M. K., & Parajuli, P. (2021) · Advances in pharmacology · doi:10.1016/bs.apha.2021.01.002 · Cited by 86
Hasan, M. N., Capuk, O., Patel, S. M., & Sun, D. (2022) · Cancers · doi:10.3390/cancers14143331 · Cited by 82
Tumor-derived exosomes in the cancer immune microenvironment and cancer immunotherapy
Tang, Q., Yang, S., He, G., Zheng, H., Zhang, S., Liu, J., Wei, S., Fan, Q., Peng, X., Li, X., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215823 · Cited by 84
Karin, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.557586 · Cited by 84
“Along with this, very recently it has been reported that targeted deletion of PD-1 from MDSC induces highly effective antitumor immunity (10).”
BackgroundThe role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy
Li, Z., Li, Y., Gao, J., Fu, Y., Hua, P., Jing, Y., Cai, M., Wang, H., & Tong, T. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119150 · Cited by 73
MDSC in Mice and Men: Mechanisms of Immunosuppression in Cancer
Vanhaver, C., van der Bruggen, P., & Bruger, A. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132872 · Cited by 84
“Tumor cells express immune checkpoint ligands such as the Programmed Cell Death-1 (PD-1) ligand (PD-L1), which binds to PD-1 on T-cells and inhibits anti-tumor responses [127].”
BackgroundInfluentialBeck, J. D., Diken, M., Suchan, M., Streuber, M., Diken, E., KOLB, L. D., Allnoch, L., Vascotto, F., Peters, D., Beißert, T., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.013 · Cited by 78
Pulanco, M. C., Madsen, A. T., Tanwar, A., Corrigan, D. T., & Zang, X. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01019-8 · Cited by 75
“Myeloid-specific deletion of PD-1 results in PD-1deficient myeloid progenitor cells with increased levels of metabolites involved in glycolysis, the pentose phosphate pathway, the citric acid cycle, and cholesterol in response to emergency myelopoiesis-related growth factors [60].”
BackgroundOrtega, M. A., Boaru, D. L., León-Oliva, D. D., Fraile‐Μartinez, O., Montero, C. G., Rios, L., Garrido-Gil, M. J., Barrena-Blázquez, S., Minaya‐Bravo, A., Rios‐Parra, A., et al. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02463-3 · Cited by 77
“…on primarily activated T lymphocytes [23], B lymphocytes [24], natural killer (NK) [25], macrophages [26], DCs [27], monocytes, myeloid cells [28], and is expressed in immune-privileged areas such as the cornea and retina, and its expression is increased by restricting other CD28 family…”
Singh, L., Muise, E. S., Bhattacharya, A., Grein, J., Javaid, S., Stivers, P., Zhang, J., Qu, Y., Joyce-Shaikh, B., Loboda, A., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0622 · Cited by 70
“They showed that even with conserved PD1 expression in T cells, myeloid cell–specific PD1 knockout resulted in an increase of T effector memory cells with enhanced functionality and mediated antitumor protection (49).”
BackgroundResultRajendran, S. H., Hu, Y., Canella, A., Peterson, C. R., Gross, A. C., Cam, M., Nazzaro, M., Haffey, A., Harmancı, A. S., Distefano, R., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112197 · Cited by 73
mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment
Haas, M., Kagey, M. H., Heath, H., Schuerpf, F., Rottman, J. B., & Newman, W. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0799 · Cited by 69
“responsive tumors; the expression of PD-L1 on tumor infiltrating myeloid cells may also be a predictive biomarker of response to anti-PD-1 therapy (27-29).”
BackgroundLandscape of natural killer cell activity in head and neck squamous cell carcinoma
Charap, A., Enokida, T., Brody, R., Sfakianos, J. P., Miles, B. A., Bhardwaj, N., & Horowitz, A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001523 · Cited by 81
Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
Kotanides, H., Li, Y., Malabunga, M., Carpenito, C., Eastman, S. W., Shen, Y., Wang, G., Inigo, I., Surguladze, D., Pennello, A. L., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0304 · Cited by 65
“PD-1 antibody blockade on myeloid cells, or myeloid-specific PD-1 genetic ablation, induces antitumor immunity through metabolic reprogramming that leads to increased T effector memory cells (42).”
BackgroundMatteis, R. D., Flak, M. B., Gonzalez-Nuñez, M., Austin‐Williams, S., Palmas, F., Colas, R. A., & Dalli, J. (2022) · Science Advances · doi:10.1126/sciadv.abl5420 · Cited by 70
“Underscoring the importance of this mechanism in this pathogenic process are findings from recent studies that demonstrate that inhibition of PD-1 in myeloid cells, including macrophages, represents a key mechanism of antitumor immunity mediated by PD-1 blockade in experimental systems ( 31 ).”
Appleton, E. S., Hassan, J., Hak, C. C. W., Sivamanoharan, N., Wilkins, A. C., Samson, A., Lab), M. O. (., Harrington, K. J., Melcher, A. A., & Wennerberg, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.754436 · Cited by 68
Metadata
- Authors
- Strauss, L., Mahmoud, M. A. A., Weaver, J. D., Tijaro-Ovalle, N. M., Christofides, A., Wang, Q., Pal, R., Yuan, M., Asara, J., Patsoukis, N., & Boussiotis, V. A.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Boussiotis, Vassiliki A.
- ORCID
- Venue
- Science Immunology
- Published
- 2020-01-03
- Volume
- 5
- Issue
- 43
- ISSN
- 2470-9468 (ISSN-L)
- PMC
- PMC7183328
- OpenAlex
- W2997277554
- Cited by
- 437
- References
- 73
- Citations by year
- 2026: 30 · 2025: 51 · 2024: 67 · 2023: 83 · 2022: 70 · 2021: 77 · 2020: 59
- FWCI
- 26.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA183605, P01CA142106, R01CA212605)
- National Institute of Allergy and Infectious Diseases (R56AI098129)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R21AR073494)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, myeloid cells, antitumor immunity, myeloid-derived suppressor cells, good manufacturing practices, emergency myelopoiesis, myeloid progenitor cells, cholesterol metabolism, metabolic reprogramming, macrophage differentiation, dendritic cell differentiation, anti-PD-1 therapy, tumor immunology
- MeSH terms
- Animals, Cell Differentiation, Colonic Neoplasms, Female, Male, Melanoma, Mice, Inbred C57BL, Mice, Transgenic, Myeloid Cells, Cell Line, Tumor, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.